Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease.

ABSTRACT:

Background/aims

The achievement of endoscopic remission is an important therapeutic goal in the treatment of inflammatory bowel diseases (IBD). We aimed to evaluate the role of fecal calprotectin (FCP) and ischemia-modified albumin (IMA) as biomarkers for evaluating IBD disease activity.

Methods

A total of 48 patients with IBD (20 with ulcerative colitis and 28 with Crohn's disease) were included in this study. FCP and serum C-reactive protein levels, erythrocyte sedimentation rate, and IMA were measured in patients with IBD and compared with endoscopic findings.

Results

Elevated FCP and serum IMA levels were significantly associated with endoscopic non-mucosal healing. The correlation between FCP and IMA was not significant. Analysis of the receiver operating charact

SUBMITTER: Lee SB 

PROVIDER: S-EPMC10850695 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature